The epidermis functions to create a barrier to protect from water loss and exclude foreign substances and microorganisms. It consists of a multilayered stratified epithelium with viable basal, spinous, and granular layers and a dead cornified layer (stratum corneum). The epidermal barrier is maintained and continuously regenerated by terminally differentiating keratinocytes, in a highly organized process called cornification ([@bib10]). After the proliferating basal keratinocytes detach from the underlying basement membrane, they are committed to terminal differentiation and form the cornified layer, which consists of flattened cell remnants (corneocytes) surrounded by insoluble lipids. These detached suprabasal keratinocytes undergo several transcriptional and morphological changes during their translocation to the skin surface. Although these morphogenetic changes during epidermal stratification are well documented, the molecular processes of terminal differentiation, which are crucial for the development and homeostasis of the epidermal barrier, are not well understood ([@bib6]).

The cornification process of granular keratinocytes begins with the formation of the cornified envelope (CE), an insoluble protein structure which is stabilized by trans-glutaminases (TGMs). It replaces the plasma membrane and functions as a scaffold for the attachment of insoluble lipids ([@bib10]). The TGMs 1 and 3 are responsible for the characteristic resistance and insolubility of the CE because they cross-link its structural components like involucrin, loricrin, filaggrin, and the small proline-rich proteins. Specifically, the cytosolic TGM3 cross-links various CE components into small oligomers, which are then translocated and cross-linked onto the growing CE at the cell periphery by the membrane-bound TGM1 ([@bib22]). A well balanced equilibrium of corneocyte differentiation and their controlled release from the skin surface (desquamation) is crucial to maintain the epidermal barrier and ensure its renewal every 3 wk ([@bib6]). The physiological relevance of both TGMs in skin is highlighted by the lethality of *Tgm1^−/−^* and *Tgm3^−/−^* mice ([@bib28]).

The epidermal growth factor receptor (EGFR) is most prominently expressed in proliferating basal keratinocytes and to a lesser degree in suprabasal keratinocytes. It supports basal keratinocyte proliferation and delays apoptosis in suprabasal keratinocytes that have lost their interaction with the matrix ([@bib46]; [@bib47]; [@bib54]). EGFR deficiency causes defects in hair follicle development and immature epidermal differentiation with inflammatory skin reactions ([@bib39]; [@bib42]; [@bib57]; [@bib63]; [@bib58]), and anti-EGFR therapy in cancer patients commonly induces dermatologic side effects including xerotic itchy skin ([@bib32]). Although these observations corroborate the significance of EGFR signaling in skin homeostasis, little is currently known about the role of EGFR signaling in maintaining the epidermal barrier and in suppressing chronic inflammatory skin disease.

ADAM17 (a disintegrin and metalloproteinase 17) is a membrane-anchored metalloproteinase that is a crucial upstream regulator of EGFR signaling ([@bib48]; [@bib26]; [@bib60]) and is responsible for the cleavage of pro-TNF ([@bib5]; [@bib41]). Mice lacking ADAM17 die at birth, presumably as a result of defects in heart development, although other organs, such as the lung, skin, and mammary epithelia were also affected ([@bib48]; [@bib26]; [@bib60]). In that respect, *Adam17^−/−^* mice nearly phenocopy *Egfr^−/−^* mice or mice lacking the EGFR ligands TGF-α, HB-EGF, or amphiregulin, indicating an in vivo relevance of ADAM17 in EGFR processing ([@bib48]; [@bib26]; [@bib8]; [@bib60]). This notion is supported by cell-based assays, in which the shedding of several EGFR ligands depended on ADAM17 ([@bib52]). Moreover, ADAM17-dependent EGFR activation protects hepatocytes from apoptosis during drug-induced toxicity ([@bib43]) and supports intestinal proliferative regeneration in experimental colitis ([@bib12]). Because very little is currently known about the role of ADAM17 in postnatal epithelial barrier homeostasis under physiological conditions, the goal of this study was to analyze how conditional inactivation of ADAM17 in keratinocytes (*A17^ΔKC^*) affects the development and maintenance of the epidermal barrier.

RESULTS
=======

Keratinocyte-specific ADAM17 deficiency results in severe postnatal epidermal barrier defects
---------------------------------------------------------------------------------------------

To analyze the function of ADAM17 in skin, we crossed mice with floxed alleles of ADAM17 ([@bib23]) with *keratin14*-Cre knockin mice (*Krt14-Cre*) to generate mice lacking ADAM17 in keratinocytes (*A17^ΔKC^*). Western blot analysis confirmed the deletion of ADAM17 in epidermal splits from *A17^ΔKC^* mice ([Fig. 1 A](#fig1){ref-type="fig"}). An analysis of the expression pattern of *Krt14*-Cre using the ROSA26-lacZ reporter confirmed that it was restricted to the squamous epithelia of the skin and mucosa, as previously reported ([@bib66]; not depicted).

![**Keratinocyte-specific ADAM17 deficiency results in postnatal epidermal barrier defects.** (A) Western blot analysis to detect ADAM17 in lysates from P3 epidermal splits of control (Ctrl) or *A17^ΔKC^* mice. (B) Newborn *A17^ΔKC^* mice and their littermate controls. 7.5% of *A17^ΔKC^* newborn mice had open eyes at birth, indicated by arrow. (C) Dry scaly skin of *A17^ΔKC^* mice at P19. (D) Body weight of *A17^ΔKC^* versus control mice at different ages (*n* ≥ 4). (E) Survival curve of *A17^ΔKC^* mice (*n* = 100) versus controls (Ctrl, *n* = 25). Mantel-Cox test: \*\*\*, P \< 0.001. (F) Serum sodium concentration of *A17^ΔKC^* versus control mice between P15 and P25. (G) Toluidine blue dye penetration assays were performed with newborn mice (P1), P10, and P15 animals indicating outside-in barrier defects (*n* = 3 per age group). Blue staining of the umbilical cord and the cut tail at P1 is a positive control. (H) TEWL in *A17^ΔKC^* and control littermates at P8, P10, P15, and P19 (*n* ≥ 4 for P8; *n* ≥ 8 for P10, P15, and P19). (I) Preparation of CEs from 25-mm^2^ P15 back skin samples. CE clustering is indicated by the arrow. Results: mean ± SD. Student's *t* test: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. Bar, 20 µm.](JEM_20112258_Fig1){#fig1}

Newborn *A17^ΔKC^* mice had no evident skin defects ([Fig. 1 B](#fig1){ref-type="fig"}) or histological abnormalities in their epidermis (not depicted). About 7.5% of *A17^ΔKC^* mice were born with open eyes ([Fig. 1 B](#fig1){ref-type="fig"}), whereas all *Adam17^−/−^* mice (complete knockout) have open eyes at birth ([@bib48]; [@bib23]), suggesting that other cells besides keratinocytes contribute to this phenotype in *Adam17^−/−^* mice. However, starting at P19, macroscopic epidermal defects became evident, with dry scaly skin in the face, the area surrounding the snout, the ventral neck and chest ([Fig. 1 C](#fig1){ref-type="fig"}), and the tail (not depicted), suggesting a compromised epidermal barrier in *A17^ΔKC^* mice.

Epidermal barrier defects lead to water loss, weight loss, electrolyte imbalances, and loss of skin turgor ([@bib56]). Although the Mendelian distribution of the offspring of *Adam17^flox/wt^/Krt14-Cre × Adam17^flox/flox^* mice was normal (not depicted) and *A17^ΔKC^* mice had a normal weight compared with littermate controls at birth and the first days thereafter, their weight was reduced by 5% at postnatal day 8 (P8) and ∼30% at P20 ([Fig. 1 D](#fig1){ref-type="fig"}). Most of the *A17^ΔKC^* mice died between P21 and P29, although some lived up to 6 mo ([Fig. 1 E](#fig1){ref-type="fig"}). The mean weight of surviving *A17^ΔKC^* mice was about half that of control animals ([Fig. 1 D](#fig1){ref-type="fig"}). Moreover, *A17^ΔKC^* mice had reduced skin turgor and significantly increased serum sodium levels ([Fig. 1 F](#fig1){ref-type="fig"}). The combination of hypernatremia and weight loss suggested dehydration as the underlying cause. None of the other genotypes (*Adam17*^wt/wt^/*Krt14-Cre*, *Adam17^flox/^*^wt^*/Krt14-Cre*, *Adam17^flox/^*^wt^, or *Adam17^flox/^*^flox^, referred to as *Ctrl*) displayed any evident phenotype (unpublished data). Together, these data suggest that the postnatal lethality in *A17^ΔKC^* mice was caused by water loss as the result of an epidermal barrier defect that developed after birth.

We next used a dye penetration assay to examine the integrity of the skin barrier. The epidermis of newborn mice and P10 pups was completely resistant to toluidine blue penetration, whereas P15 animals showed dye permeability in the mechanically stressed areas, including the face around their snout, genitals, anus, and paws ([Fig. 1 G](#fig1){ref-type="fig"}). Transepidermal water loss (TEWL) of the skin surface was first detectable at P10, and subsequently increased with age, as documented at P15 and P19 ([Fig. 1 H](#fig1){ref-type="fig"}), indicating severe inside-out barrier defects. Because epidermal lipids are crucial to form the protective barrier against water loss in the stratum corneum, we stained P15 skin sections with the lipophilic dye Nile red. No significant differences in epidermal lipid content and distribution were seen in *A17^ΔKC^* versus control mice (unpublished data). Impaired integrity of the CE has been linked to skin barrier defects ([@bib55]). CE preparations derived from P15 biopsies of *A17^ΔKC^* back skin showed 50% reduced size and were clustered in conglomerates that were not seen in preparations of control skin ([Fig. 1 I](#fig1){ref-type="fig"}), indicating abnormal development and an immature state.

Dysregulated epidermal differentiation markers and decreased TGM activity in *A17^ΔKC^* skin
--------------------------------------------------------------------------------------------

Skin integrity depends on the renewal of terminally differentiated keratinocytes, which assemble the CE. Histological analysis of back skin from *A17^ΔKC^* mice and littermate controls at P2 failed to uncover evident structural defects within the epidermal layers or differences in the number of proliferating basal keratinocytes (unpublished data). In contrast, epidermal differentiation was significantly altered, with increased production of the early differentiation marker keratin1 and the terminal differentiation marker loricrin, a major component of the CE ([@bib30]), and decreased production of involucrin and TGM3, which are needed to initiate cornification on the skin surface, whereas the expression of keratin 14, a structural component of the basal layer, remained unchanged ([Fig. 2 A](#fig2){ref-type="fig"}). Thus, epidermal ADAM17 deficiency increases early and dysregulates late keratinocyte differentiation.

![**Decreased TGM activity and altered expression of epidermal differentiation markers in *A17^ΔKC^* skin.** (A) Western blots of epidermis lysates analyzing epidermal keratin1, keratin14, loricrin, and involucrin expression in *A17^ΔKC^* skin (quantification: *n* = 5). (B) In situ detection of TGM activity in *A17^ΔKC^* and control epidermis at P2 and P10, with TGM activity in the stratum granulosum of control epidermis indicated by arrows (quantification: *n* = 6). (C) Quantitative RT-PCR from total RNA of P10 *A17^ΔKC^* skin analyzing TGM1, TGM3, and keratin14 (*n* = 4). (D) Quantitative immunoblot analysis from P10 skin lysates analyzing TGM1 and TGM3 in *A17^ΔKC^* animals (*n* = 4). (E) Detection of serine protease activity in P10 skin with SBTI Alexa Fluor 488 conjugates in the stratum granulosum and stratum corneum in control skin (arrows) and in *A17^ΔKC^* skin (*n* = 3). The negative controls with an excess of unlabeled SBTI resulted in diminished signals. (F) RT-PCR analysis from total RNA derived from P10 skin for serpina3a, serpina3n, and keratin14 (*n* = 4). The dashed lines in B and E represent the basement membrane. Bars, 20 µm. Results: mean ± SD. Students *t* test: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20112258R_Fig2){#fig2}

The TGMs 1 and 3 are crucial to forming the CE ([@bib22]). When we used a fluorometric in situ assay with a synthetic TGM substrate ([@bib51]) to evaluate whether the TGM expression or activity was altered in *A17^ΔKC^* keratinocytes, we found comparable epidermal TGM activity to control littermates at P2 but significantly reduced activity in *A17^ΔKC^* epidermis at P10 ([Fig. 2 B](#fig2){ref-type="fig"}). Moreover, quantitative RT-PCR analysis revealed similar expression of both TGMs at P2 (not depicted) but significantly reduced expression at P10 in *A17^ΔKC^* skin compared with controls ([Fig. 2 C](#fig2){ref-type="fig"}). An immunoblot of P10 skin showed significant reduction of TGM3 in *A17^ΔKC^* animals but comparable TGM1 levels ([Fig. 2 D](#fig2){ref-type="fig"}). Finally, there was a thickened stratum corneum (not depicted) and elevated CE numbers in *A17^ΔKC^* skin ([Fig. 1 I](#fig1){ref-type="fig"}, right), similar to the hyperkeratotic stratum corneum with significantly improved TEWL found in TGM1^−/−^ skin grafts on nude mice as a compensatory mechanism for the skin permeability defects ([@bib31]).

Thickening of the cornified layer can be caused by reduced desquamation of corneocytes, which depends on processing by kallikreins ([@bib17]). When we probed *A17^ΔKC^* skin sections with fluorescently labeled soybean protease inhibitor (SBTI), which binds kallikreins ([@bib18]), we found significantly reduced staining in the *A17^ΔKC^* stratum corneum at P10 ([Fig. 2 E](#fig2){ref-type="fig"}). This indicates a strong reduction of serine protease activities, which can be caused by decreased protease expression or increased expression of inhibitors. A skin DNA microarray from P10 skin of *A17^ΔKC^* animals showed up-regulation of two serine protease inhibitors, serpina3a and a3n, compared with controls, which was confirmed by quantitative RT-PCR ([Fig. 2 F](#fig2){ref-type="fig"}).

Dysregulated terminal differentiation in *A17^ΔKC^* skin
--------------------------------------------------------

To elucidate whether the altered expression of terminal differentiation markers is cell autonomous, we analyzed their protein expression in a suspension culture of extracellular matrix (ECM)--disrupted primary *A17^ΔKC^* keratinocytes and controls ([@bib65]; [@bib13]). *A17^ΔKC^* keratinocytes showed significantly reduced levels of the TGMs 1 and 3 and concomitantly increased loricrin production ([Fig. 3 A](#fig3){ref-type="fig"}), suggesting cell-autonomous regulatory mechanisms. Furthermore, the TGM activity in *A17^ΔKC^* keratinocytes was strongly reduced in suspension cultures ([Fig. 3 B](#fig3){ref-type="fig"}).

![***A17^ΔKC^* keratinocytes exhibit cell autonomous dysregulated terminal differentiation.** (A) Western blot of keratinocytes for expression of ADAM17 (AD17), TGMs 1 and 3, and loricrin (Lor) in *A17^ΔKC^* keratinocytes and controls (Ctrl). *n* = 3. (B) In vitro TGM activity in 24-h suspension-cultured control keratinocytes (arrows) and in *A17^ΔKC^* keratinocytes (*n* = 6). Wild-type keratinocytes probed with an excess of EDTA served as negative control. Bar, 20 µm. Results: mean ± SD, students *t* test: \*, P \< 0.05; \*\*, P \< 0.01.](JEM_20112258R_Fig3){#fig3}

Skin barrier defects in *A17^ΔKC^* animals induce IL-36α, immune cell influx, and hyperproliferative epidermis
--------------------------------------------------------------------------------------------------------------

The microarray analysis on P10 skin identified the IL-1 family member IL-36α as the most prominent proinflammatory cytokine in *A17^ΔKC^* skin. A quantitative PCR (qPCR) analysis for several IL-1 family members (IL-1α, IL-1β, IL-1ra, IL-36α, IL-36β, IL-36Ra, IL-18, and IL-18bp) showed no elevation at P2 and P6, in contrast to the significant increase of the keratinocyte-derived cytokines IL-36α, IL-36β, and IL-18 ([@bib9]; [@bib59]) at P10 ([Fig. 4 A](#fig4){ref-type="fig"}). qPCR from epidermis splits confirmed their epidermal origin ([Fig. 4 B](#fig4){ref-type="fig"}). Thus *A17^ΔKC^* keratinocytes begin to express proinflammatory cytokines at the onset of detectable epidermal barrier defects. In addition, the expression of the monocyte chemoattractant protein 1/CCL2 in the skin was significantly increased from P10, whereas the neutrophilic chemokine GRO-α/CXCL1 showed increased expression at P16 ([Fig. 4 C](#fig4){ref-type="fig"}).

![**Skin barrier defects result in increased IL-36α, immune cell infiltration, and epidermal thickening.** (A) qPCR analysis of P2-P19 skin for IL-36α, IL-36β, and IL-18. (B) qPCR analysis of P10 epidermis for IL-36α, IL-36β, and IL-18 (*n* = 4). (C) qPCR analysis of P2--P19 skin for CCL2, and CXCL1 relative to GAPDH. *n* ≥ 3. (D) Flow cytometry of skin cell suspensions gated for CD45^+^ and further analyzed for neutrophils (CD11b^+^Ly6G^+^) and inflammatory macrophages (CD11b^+^Ly6G^−^Ly6C^+^F4/80^+^). P10 (*n* = 5), P15 (*n* = 4), and P19 (*n* ≥ 8) are shown. (E) Sections of H&E-stained *A17^ΔKC^* skin at P21 showed neutrophil accumulation on the surface and adjacent to hair follicles (black arrows). (F) Percentage of Ki67-positive keratinocytes in *A17^ΔKC^* skin at P21 (*n* = 3). Bars, 50 µm. Results: mean ± SD. Student's *t* test: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20112258_Fig4){#fig4}

To evaluate the potential consequences of increased cytokine and chemokine expression in the skin of *A17^ΔKC^* mice, we used histochemistry and flow cytometry of single-cell suspensions from skin to identify infiltrating immune cells. No infiltrating immune cells were detectable at P10, but a significant increase in inflammatory macrophages (defined as CD45^+^CD11b^+^Ly6G^−^Ly6C^+^F4/80^+^) was evident at P15 ([Fig. 4 D](#fig4){ref-type="fig"}, top). At P19, there was a strongly increased infiltration of neutrophils (identified as CD45^+^CD11b^+^Ly6G^+^) and inflammatory macrophages ([Fig. 4 D](#fig4){ref-type="fig"}) and significantly elevated numbers of mast cells (not depicted). In contrast, there was no detectable elevation of CD3^+^ T cell or CD19^+^ B cell populations (unpublished data). Histological analysis of trunk and ear skin of *A17^ΔKC^* mice at P21 showed significant neutrophilic infiltrates on the skin surface or close to the hair follicle canals ([Fig. 4 E](#fig4){ref-type="fig"}). The inflammatory responses in the skin most likely led to keratinocyte proliferation. At P10, when no immune cell infiltrates were detectable, the proliferating basal keratinocyte layer showed no changes (not depicted). At P21 there was significant epidermal hyperplasia with increased numbers of Ki67-positive cells ([Fig. 4 F](#fig4){ref-type="fig"}), coinciding with increased immune cell infiltrates.

Inflammatory macrophages are not the primary cause of the skin barrier defect of *A17^ΔKC^* mice
------------------------------------------------------------------------------------------------

The development of hyperproliferative skin diseases can potentially be triggered by skin macrophages ([@bib61]). However, the absence of inflammatory macrophages at P10 when epithelial barrier defects first became evident argued against such a mechanism in *A17^ΔKC^* mice. Yet because inflammatory macrophages were present at an early stage of barrier breakdown and preceded infiltration of neutrophils ([Fig. 4 D](#fig4){ref-type="fig"}), a significant contribution of macrophages as a primary cause of the epithelial barrier defects was still possible. To address this possibility, we depleted the macrophages in *A17^ΔKC^* skin by subcutaneous injection of clodronate-loaded liposomes starting at P8---before appearance of the first signs of the phenotype---until P19. This treatment dramatically reduced the number of macrophages in the dermis compared with PBS-liposome treated *A17^ΔKC^* littermates ([Fig. 5, A and B](#fig5){ref-type="fig"}, top) but did not improve epidermal TGM activity ([Fig. 5 B](#fig5){ref-type="fig"}, bottom) or the TEWL ([Fig. 5 C](#fig5){ref-type="fig"}).

![**Infiltrating skin macrophages do not cause the skin barrier defects in *A17^ΔKC^* mice.** For depletion of dermal macrophages, *A17^ΔKC^* mice were subcutaneously injected with clodronate-loaded liposomes (*A17^ΔKC^* + Clod) or PBS-loaded liposomes (*A17^ΔKC^* + PBS, Ctrl) into the back skin. (A) Flow cytometry of skin macrophages at P19 gated for CD11b^+^Ly6G^−^ and further analyzed for skin macrophages (CD45^+^F4/80^+^; *n* = 5). (B) Immunofluorescence staining of *A17^ΔKC^* skin with anti-F4/80 antibodies to detect macrophages (top) and for TGM activity (bottom, arrows in Ctrl; *n* ≥ 5 per group). Bars, 20 µm. (C) TEWL from the back skin of *A17^ΔKC^* mice injected with clodronate-loaded (*A17^ΔKC^* + Clod) or control (*A17^ΔKC^* + PBS) liposomes and from control mice was detected from P8 to P19 (*n* ≥ 5 per group). Data are mean ± SD. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20112258_Fig5){#fig5}

*Egfr^ΔKC^* mice have similar epidermal barrier defects and dysregulated keratinocyte differentiation to those of *A17^ΔKC^* mice
---------------------------------------------------------------------------------------------------------------------------------

ADAM17 is the principal sheddase for several ligands of the EGFR ([@bib48]; [@bib26]; [@bib8]; [@bib60]). Western blot analysis of phosphorylated EGFR (pEGFR) revealed a pronounced reduction of pEGFR in *A17^ΔKC^* skin lysates with similar levels of total EGFR ([Fig. 6 A](#fig6){ref-type="fig"}). *Egfr^−/−^* mice have defects in hair and epithelial development ([@bib39]; [@bib57]; [@bib58]) resembling those in *A17^ΔKC^* mice; however, the effects of EGFR deficiency on epidermal barrier and CE formation have not been previously investigated.

![***Egfr^ΔKC^* mice have similar epidermal differentiation and barrier defects as *A17^ΔKC^* mice.** (A) Western blot of *A17^ΔKC^* skin lysates for phospho-EGFR (pEGFR) and total EGFR compared with controls (Ctrl; *n* = 4). (B) Immunoblot analysis of epidermal splits of *Egfr^ΔKC^* skin for EGFR. (C) Survival curve of control (Crtl) versus *Egfr^ΔKC^* littermate mice (*n* = 30). Mantel-Cox test: \*\*\*, P \< 0.001. (D) Body weight of *Egfr^ΔKC^* versus control mice at different ages (*n* ≥ 4). (E) Pronounced toluidine blue dye penetration around the snout and the upper trunk of P15 *Egfr^ΔKC^* animals (representative of three animals). (F) TEWL from *Egfr^ΔKC^* mice compared with controls at P10 and P19 (*n* ≥ 4). (G) Western blot of P3 back skin with involucrin antibodies in *Egfr^ΔKC^* versus control skin (Ctrl). *n* ≥ 3. (H) In situ TGM activity (arrows) in P10 skin from *Egfr^ΔKC^* epidermis compared with controls (Ctrl; *n* = 3). The dashed line represents the basement membrane. Bar, 20 µm. (I) qPCR with total RNA from P7, P12, and P19 skin for IL36α, Ccl2, and Cxcl1. (J) Flow cytometry of P19 skin cell suspensions for neutrophilic infiltrates (CD45^+^CD11b^+^Ly6G^+^; *n* = 6). Results: mean ± SD. Student's *t* test: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20112258_Fig6){#fig6}

Previously described *Egfr^ΔKC^* mice in a SV129/CL57BL6/FVB background were viable and fertile with wavy hair ([@bib34]), although the severity of EGFR knockout mice phenotypes depends on the genetic background ([@bib57]; [@bib63]). Therefore, we generated *Egfr^ΔKC^* mice in the SV129/CL57BL6 background of the *A17^ΔKC^* mice. Lack of EGFR expression in epidermal splits was confirmed by immunoblot ([Fig. 6 B](#fig6){ref-type="fig"}). Furthermore, expression of ADAM17 in *Egfr^ΔKC^* skin was comparable with littermate controls (unpublished data). *Egfr^ΔKC^* mice developed very similar phenotypes to those of *A17^ΔKC^* mice, including curly whiskers and a 10% penetrance of open eyes at birth, delayed hair outgrowth, shortened and disorganized hair follicles at P10, and dry scaly skin on the face, scalp, ventral upper trunk, and tail at P19 (unpublished data). *Egfr^ΔKC^* mice showed 85% lethality between P18 and P25, with survivors living up to 6 mo ([Fig. 6 C](#fig6){ref-type="fig"}) with pronounced growth retardation and ∼50% of maximal weight loss ([Fig. 6 D](#fig6){ref-type="fig"}). *Egfr^ΔKC^* mice had significant dye penetration on the face, upper trunk, and paws at P15 ([Fig. 6 E](#fig6){ref-type="fig"}) and significant TEWL at P10, which was strongly elevated at P19 ([Fig. 6 F](#fig6){ref-type="fig"}). Similar to *A17^ΔKC^* mice, we found a significant reduction of the late terminal differentiation marker involucrin in the *Egfr^ΔKC^* epidermis ([Fig. 6 G](#fig6){ref-type="fig"}) and increased keratin1 and loricrin mRNA expression (not depicted). Moreover, TGM activity was unchanged in the epidermis of *Egfr^ΔKC^* mice at P2 (not depicted) but significantly reduced at P10 compared with controls ([Fig. 6 H](#fig6){ref-type="fig"}). Analysis of cytokine expression in the skin of *Egfr^ΔKC^* mice showed no elevation of IL-1α, IL-1β, IL-1ra, and IL-36Ra, but significantly elevated IL-36α and Ccl2 at P12 ([Fig. 6 I](#fig6){ref-type="fig"}) and induction of Cxcl1, as well as strongly increased neutrophil and inflammatory macrophage infiltrates at P19 ([Fig. 6, I and J](#fig6){ref-type="fig"}; and not depicted). Thus the pathological changes in *Egfr^ΔKC^* mice closely resembled those observed in *A17^ΔKC^* mice.

The EGFR ligand TGF-α regulates epidermal differentiation
---------------------------------------------------------

Of the EGFR ligands whose shedding depends on ADAM17 ([@bib52]), TGF-α is mainly responsible for epidermal development and hair growth ([@bib35]; [@bib36]; [@bib54]). Quantitative analysis of RNA expression level of EGFR ligands in wild-type P2 skin revealed the highest levels for TGF-α, with fivefold more expression than HB-EGF and ∼2.5-fold more expression than amphiregulin or epiregulin (unpublished data).

We therefore sought to determine whether TGF-α is involved in the differentiation of primary keratinocyte cultures. When we used a Ca^2+^-induced keratinocyte differentiation assay ([@bib50]), we found that Ca^2+^ treatment increased the release of TGF-α from keratinocytes by ∼50% compared with untreated controls ([@bib15]; not depicted). When suspension cultures of keratinocytes ([@bib65]; [@bib13]) were treated with 30 ng/ml TGF-α for 48 h, we found significantly reduced keratin 1 and loricrin mRNA expression, whereas keratin 14 expression remained unchanged ([Fig. 7 A](#fig7){ref-type="fig"}). Thus, stimulation of the EGFR by TGF-α had the opposite effect on the keratinocyte differentiation markers keratin1 and loricrin as deletion of ADAM17 ([Fig. 2 A](#fig2){ref-type="fig"}). Importantly, the reduced TGM activity in ECM-disrupted *A17^ΔKC^* keratinocytes was nearly completely restored by recombinant TGF-α ([Fig. 7 B](#fig7){ref-type="fig"}), suggesting that the lack of EGFR activation is the major cause of the loss of TGM activity in ADAM17-deficient keratinocytes.

![**EGFR stimulation with TGF-α regulates terminal differentiation.** (A) ECM-disrupted keratinocyte suspensions were incubated with and without 40 ng/ml TGF-α for 48 h, and total RNA was then analyzed by qPCR for keratin1, loricrin, and keratin14 (*n* = 3). (B) Suspension cultured keratinocytes analyzed for in vitro TGM activity (arrows). Bar, 20 µm. *A17^ΔKC^* keratinocytes were cultured with 40 ng/ml TGF-α when indicated (*n* = 3 per group). (C) TGF-α ELISA in the supernatants of control and *A17^ΔKC^* keratinocytes cultured for 24 h (*n* = 7). Results: mean ± SD. Student's *t* test: \*, P \< 0.05; \*\*\*, P \< 0.001.](JEM_20112258_Fig7){#fig7}

To address the role of ADAM17/TGF-α in epidermal barrier maintenance in vivo, we first determined whether TGF-α levels are altered in *A17^ΔKC^* skin. No differences in the RNA expression or protein staining were observed in the *A17^ΔKC^* animals compared with controls (unpublished data). In addition, no significant differences in the expression of HB-EGF, amphiregulin, and epiregulin mRNA were found in *A17^ΔKC^* mice versus controls (unpublished data). However, shedding of TGF-α from primary *A17^ΔKC^* keratinocytes was strongly reduced compared with controls ([Fig. 7 C](#fig7){ref-type="fig"}).

To determine whether the lack of TGF-α shedding from the epidermis was responsible for the skin barrier breakdown and subsequent skin inflammation, we applied recombinant TGF-α or DMSO as control daily to a defined area of *A17^ΔKC^* skin from P8 to P19 and measured EGFR phosphorylation, TGM activity, compensatory serine protease activity, and immune cell infiltrates. Western blot analysis revealed a pronounced increase of phospho-EGFR and TGM3 in TGF-α--treated *A17^ΔKC^* skin ([Fig. 8 A](#fig8){ref-type="fig"}). Moreover, TGF-α significantly improved TGM activity in *A17^ΔKC^* skin at P19 ([Fig. 8 B](#fig8){ref-type="fig"}) with ∼65% increased TGM3 expression. TGF-α also reversed the compensatory reduction of serine protease activity in the stratum corneum of P19 mutant skin ([Fig. 8 C](#fig8){ref-type="fig"}) and reduced infiltrating neutrophils by 60% ([Fig. 8 D](#fig8){ref-type="fig"}) and inflammatory macrophages by 40% (not depicted). Furthermore, the daily application of recombinant TGF-α to a defined area of *Egfr^ΔKC^* skin from P8 to P19 did not affect the infiltration of immune cells or TGM activity (unpublished data).

![**Application of TGF-α reconstitutes the skin barrier.** (A) Immunoblot analysis of DMSO control versus TGF-α--treated *A17^ΔKC^* skin (*n* = 4). (B) TGM activity (arrows) in P19 control or *A17^ΔKC^* skin treated with TGF-α (*n* = 5 per group). (C) Serine protease activity (detected with SBTI Alexa Fluor 488 conjugates; arrows) in control or *A17^ΔKC^* skin treated with TGF-α (*n* = 3). The dashed lines in B and C represent the basement membrane. (D) For flow cytometric detection, the skin cell suspensions were gated for CD45 and further analyzed for neutrophils (CD11b^+^Ly6G^+^; *n* = 8 per group). Results: mean ± SD. Student's *t* test: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. Bars, 20 µm.](JEM_20112258_Fig8){#fig8}

Chronic deficiency of keratinocyte-derived ADAM17 results in atopic dermatitis-like disease
-------------------------------------------------------------------------------------------

20% of the *A17^ΔKC^* mice survived up to 6 mo, thus allowing us to examine the chronic effects of keratinocyte-ADAM17 deficiency. Older *A17^ΔKC^* mice displayed all characteristic manifestations of a defective epidermal barrier and dehydration, including dry scaly skin, significantly increased serum sodium, reduced skin turgor, and 50% weight loss (unpublished data). Furthermore, compared with control littermates, they exhibited strong scratching as a sign of intense pruritus, which is characteristic of chronic dermatitis with epidermal barrier defects ([@bib20]). Histological analysis confirmed altered epidermal differentiation, with increased expression of keratin 1 and loricrin and lower expression of involucrin, one of the initiator proteins in the cornification, suggesting dysregulated terminal differentiation ([Fig. 9 A](#fig9){ref-type="fig"}). Long-term surviving *A17^ΔKC^* mice also demonstrated pronounced epidermal hyperproliferation, similar to *A17^ΔKC^* animals at P21 ([Fig. 4 F](#fig4){ref-type="fig"}), with increased cell numbers, keratin14, keratin1, and epidermal staining of the hyperproliferation marker keratin 6, which is normally only produced in the midportion of the hair follicles of control skin ([Fig. 9 A](#fig9){ref-type="fig"}). In addition, toluidine blue staining and flow cytometry of back skin of 60-d-old mice revealed pronounced dermal accumulation of mast cells ([Fig. 9 B](#fig9){ref-type="fig"}), and strongly elevated numbers of inflammatory macrophages (CD45^+^CD11b^+^Ly6G^-^F4/80^+^) and T cell populations (CD3^+^; not depicted). The epidermal thickening was most likely induced by the severe infiltration of inflammatory cells. The prolonged skin inflammation of the *A17^ΔKC^* mice presumably also caused systemic defects with significantly increased serum concentrations of IgE und IgG1 ([Fig. 9 C](#fig9){ref-type="fig"}), splenomegaly ([Fig. 9 D](#fig9){ref-type="fig"}) and enlarged lymph nodes (not depicted), and severely decreased bone marrow B220^+^ populations ([Fig. 9 E](#fig9){ref-type="fig"}) in P60 *A17^ΔKC^* mice compared with controls. Similar pathological changes were observed in the skin of P60 *Egfr^ΔKC^* mice ([Fig. 9 B-E](#fig9){ref-type="fig"}), suggesting that impaired EGFR signaling causes these defects in *A17^ΔKC^* mice.

![**Prolonged epidermal ADAM17 deficiency leads to chronic dermatitis.** (A) Immunohistological staining of P60 epidermis with antibodies against the basal keratinocyte marker keratin14, hyperproliferation marker keratin 6, the early differentiation marker keratin1, and the terminal differentiation markers involucrin and loricrin. Arrows indicate staining localization. (B) Toluidine blue staining of back skin sections revealed a pronounced dermal accumulation of mast cells (arrows; *n* = 4). Bars: (A and B) 50 µm. (C) Concentrations of IgE and IgG1, measured by ELISA in serum of P60 animals (*n* ≥ 3). (D) Spleen weight in control, *A17^ΔKC^*, and *Egfr^ΔKC^* animals (*n* = 14). Bar, 1 cm. (E) Anti-B220 PE-stained B cell populations compared with controls in bone marrow flow cytometry (*n* ≥ 4). Data are mean ± SD. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20112258_Fig9){#fig9}

DISCUSSION
==========

The skin provides an important protective physical barrier, yet the molecular mechanisms responsible for maintaining this barrier remain poorly understood. Here we report that the ADAM17--EGFR signaling axis in keratinocytes regulates the integrity of the skin barrier by promoting terminal keratinocyte differentiation and the cross-linking activity of TGMs. Lack of ADAM17 in keratinocytes led to severe epidermal barrier defects, resulting in TEWL, inflammatory infiltrates, and increased mortality. ADAM17 regulates the skin barrier by controlling EGFR ligand shedding and EGFR signaling in keratinocytes, as indicated by lack of TGF-α shedding from *A17^ΔKC^* keratinocytes and the similar phenotype of *Egfr^ΔKC^* and *A17^ΔKC^* mice. Notably, application of TGF-α to *A17^ΔKC^* skin restored epidermal barrier integrity by stimulating skin TGM activity and thereby reducing immune infiltrates. Our findings highlight the essential role of the ADAM17--TGF-α (or other EGFR ligands)--EGFR signaling pathway in maintaining epidermal barrier homeostasis.

The integrity of the epidermal barrier depends on the continuous regeneration of the cornified layer. Cornification is a tightly controlled process, which requires coordinated keratinocyte proliferation, detachment, migration and cell death by terminal differentiation. A striking finding in the epidermis of the *A17^ΔKC^* animals was the defect in terminal keratinocyte differentiation and cornified layer formation, which was very similar to that observed in *Egfr^ΔKC^* mice. The release of the ADAM17 substrate and EGFR ligand TGF-α was increased in differentiating wild-type keratinocytes, and TGF-α stimulated the differentiation of suprabasal-like keratinocytes, as indicated by reduced keratin 1 and loricrin and increased TGM expression ([@bib15]; [@bib49]; [@bib65]; [@bib13]). Accordingly, *A17^ΔKC^* keratinocytes had increased loricrin levels and decreased TGM expression. These findings implicate ADAM17 in cell-autonomous regulation of keratinocyte differentiation and regeneration of the cornified layer through shedding of TGF-α.

Previous studies revealed immature or absent keratinization of the stratum corneum in newborn *Egfr^−/−^* mice ([@bib39]; [@bib57]). In contrast, in our study both *A17^ΔKC^* and *Egfr^ΔKC^* animals were born with normal epidermal barrier integrity. The severe inside-out barrier defects with significant TEWL and the outside-in barrier defects only became evident around postnatal day 10. The more severe phenotype of *Egfr^−/−^* and *Adam17^−/−^* knockout mice is most likely explained by the compounded effects of EGFR or ADAM17 deficiency in all tissues. Our findings suggest that ADAM17/EGFR signaling in keratinocytes only plays a minor role in the development of an intact skin barrier in utero and in newborn mice but that it is crucial for the renewal of the CE in postnatal development and adults. Consistent with our findings of a normal epidermal barrier in newborn *A17^ΔKC^* and *Egfr^ΔKC^* mice, the TGM activity, necessary for cross-linking of proteins and formation of the CE, was normal at birth but significantly decreased at P10. Interestingly, control littermates had strongly elevated expression of TGM1 and TGM3 (unpublished data) and increased TGM activity at P10 compared with P2, suggesting an increased importance of TGMs in forming and maintaining the CE as the animals grow older. Consistent with this, about a threefold increase in TGM activity was detected in adult murine skin compared with P2 skin ([@bib27]). The reduction of both TGM transcripts in *A17^ΔKC^* skin at P10 and in ADAM17 deficient keratinocytes indicate that both TGMs are regulated cell autonomously by EGFR signaling, as further corroborated by enhanced TGM expression and activity after treatment with TGF-α. Interestingly, the severity of autosomal recessive congenital ichthyosis, a disorder of keratinization caused by mutations in TGM1, correlated with the decrease in skin TGM activity ([@bib3]).

The reduced TGM activity in *A17^ΔKC^* epidermis resulted in the production of an immature CE and denser stratum corneum with significantly increased numbers of corneocytes. The strongly reduced serine protease activity in the cornified layer is likely a consequence of the decreased TGM activity because serine protease and TGM activity were normal in P2 *A17^ΔKC^* skin. Previous studies have shown that a reduced integrity of the cornified layer can be associated with a compensatory decrease in desquamation, resulting in a thickened stratum corneum that maintains skin barrier function. This effect has been documented in *Tgm1^−/−^* skin grafts on nude mice, which formed a hyperkeratotic stratum corneum with significantly reduced TEWL ([@bib31]). Desquamation is an active process, which depends on a well balanced degradation of the corneodesmosomal adhesion molecules by the serine proteases kallikrein 7 and 5, which in turn are activated by other kallikreins ([@bib17]). Thus the decreased serine protease activity in the *A17^ΔKC^* skin is most likely responsible for the reduced desquamation. Interestingly, kallikreins were not down-regulated in microarrays of *A17^ΔKC^* skin (unpublished data) but instead serpina3 members were up-regulated, which can irreversibly inhibit several kallikreins and thereby regulate corneocyte detachment ([@bib11]; [@bib45]; [@bib4]).

The expression of proinflammatory cytokines in keratinocytes was most likely triggered by epidermal barrier defects because it increased at the same time that significant TEWL on the skin surface first became apparent and coincided with reduced TGM activity in *A17^ΔKC^* skin. Previous studies have shown that acute skin barrier defects led to epithelial cytokine production, especially of IL-1 family members ([@bib67]; [@bib69]; [@bib68]). We found that skin barrier defects in *A17^ΔKC^* preferentially up-regulated the expression of the novel IL-1 family member IL-36α ([@bib59]) and, to a lesser degree, IL-36β and IL-18. We detected similar IL-1 family member expression patterns in the skin of *Egfr^ΔKC^* animals. The proinflammatory effects of IL-36α have been demonstrated in vivo by transgenic overexpression of IL-36α in the epidermis ([@bib9]) and by the development of generalized pustular psoriasis in patients with an inactivating mutation in the IL-36 receptor antagonist (IL-36Ra), a protein which normally blocks activation of the IL-36 receptor (also referred to as IL-1 receptor-related protein type 2; IL-1Rrp2) by IL36α, β, and γ ([@bib38]). Interestingly, pronounced epidermal expression of IL-36β was previously reported in epidermis-specific *FGFR1/FGFR2* double knockout mice, which develop progressive skin barrier defects associated with immune cell infiltrates, comparable with the *A17^ΔKC^* mice ([@bib68]). Recent studies have shown that the FGFR2 activates the EGFR and ERK1/2 by stimulating ADAM17 and release of EGFR ligands, providing a possible explanation for the similar phenotypes of *FGFR1/FGFR2* double knockout mice and *A17^ΔKC^* mice ([@bib37]). Thus, our findings support a model in which EGFR signaling in the epidermis has immunoregulatory functions by maintaining terminal keratinocyte differentiation.

Over time, the surviving *A17^ΔKC^* mice developed a chronically thickened epidermis, dry skin, severe inflammatory dermal infiltrates, and systemic myeloproliferative disease. [@bib44] recently described a similar inflammatory skin phenotype in *A17^ΔKC^* mice but proposed that it is caused by the loss of a putative ligand-independent Notch activation by ADAM17, which, in turn, would normally suppress the production of thymic stromal lymphoprotein (TSLP) in adult skin. However, another study has shown that TSLP is produced as a consequence of skin barrier defects in general and does not depend on loss of Notch signaling ([@bib14]). Importantly, we demonstrate that the invasion of inflammatory cells is a consequence of the skin barrier defects, and not the cause, because skin defects develop in *A17^ΔKC^* mice before inflammatory infiltrates and are not reversed by macrophage depletion with clodronate. Moreover, our study identifies EGFR-dependent regulation of TGMs, which are directly responsible for establishing the skin barrier, as the most likely basis of the skin defect in *A17^ΔKC^* mice. This mechanism is further supported by the finding that *Egfr^ΔKC^* mice develop chronic dermatitis and systemic myeloproliferative disease, just like *A17^ΔKC^* mice, and by rescue experiments of *A17^ΔKC^* mice with the EGFR ligand and ADAM17 substrate TGF-α. Therefore, we conclude that chronic dermatitis and systemic myeloproliferation in ADAM17 knockout mice are late manifestations of persistent EGFR ligand deficiency and the resulting defective skin barrier. In this context, it should also be noted that previous studies have demonstrated both agonistic and antagonistic cross talk between the EGFR and Notch pathways ([@bib70]; [@bib21]; [@bib16]; [@bib1]), suggesting that the reduced Notch signaling observed by [@bib44] in *A17^ΔKC^* skin could also be explained by lack of EGFR activation. Finally, both *A17^ΔKC^* and *Egfr^ΔKC^* mice showed an outside-in barrier defect, which is thought to contribute to the pathogenetic mechanism of atopic dermatitis by exposing the skin to exogenous agents or antigens, which then trigger immune reactions ([@bib25]; [@bib40]).

Of the EGFR ligands that are shed by ADAM17 ([@bib52]), TGF-α is the principal growth factor required for epidermal differentiation and hair growth in mice ([@bib35]; [@bib36]) and it is the most highly expressed EGFR ligand in skin. However, other EGFR ligands also regulate important keratinocyte functions, such as keratinocyte migration, which is stimulated by heparin binding EGF (HB-EGF) and increased keratinocyte proliferation in psoriasis-like cutaneous pathologies by amphiregulin ([@bib54]; [@bib37]). It is therefore possible that several ADAM17-dependent EGFR ligands coordinately support epidermal barrier development and maintenance.

The EGFR signaling pathway is an established target for treatment of various cancers ([@bib24]). Interestingly, dermatologic side effects frequently appear during the first 3 wk of treatment, especially on skin regions with high density of sebaceous glands, like the scalp, face, and upper chest. These side effects include inflammatory papulopustular acneiform rash, hair changes, itching (pruritus), and skin dryness (xerosis), whereas the mostly sterile inflammatory rash accompanied with itchy xerotic skin is the most frequent manifestation ([@bib46]; [@bib33]). Recently, similar anti-EGFR antibody-induced neutrophil-rich skin inflammation combined with epithelial thickening of the face und upper trunk has been reported in immunodeficient (SCID) mice after the 3rd wk of treatment ([@bib62]). Although the clinical manifestations are well characterized, the direct mechanistic cause of these inflammatory skin reactions is still unclear ([@bib32]). Because depletion of ADAM17 or the EGFR in the epidermis lead to xerotic inflammatory skin, preferentially at sites with high density of sebaceous glands, it is likely that the gene-targeted mice and patients share the same mechanistic cause of epidermal pathology. This notion is further supported by a recent report of the first inactivating mutation in the *ADAM17* gene borne by a human patient, who has developed an inflammatory skin and bowel disease with neonatal onset, strongly elevated T cell skin infiltrates, and reduced TGM1 expression in the skin ([@bib7]). Thus, the insights gained from *A17^ΔKC^* mice have significant translational relevance. Understanding the biological consequences of the blockage of ADAM17-dependent EGFR signaling in the skin could lead to the development of better therapeutic strategies for the dermatologic side effects of EGFR antagonists in cancer patients and the treatment of patients carrying mutant alleles of ADAM17.

MATERIALS AND METHODS
=====================

### Animals.

The generation of *Adam17^flox/flox^* and *EGFR^flox/flox^* mice has been described previously ([@bib23]; [@bib34]). Both strains were crossed with keratin-14-Cre (*Krt14-Cre*) transgenic mice (004782, STOCK Tg(KRT14-cre)1Amc/J; The Jackson Laboratory). *Adam17^flox/+^Krt14-Cre* mice were crossed with *Adam17^flox/flox^* mice to generate *Adam17^flox/flox^ Krt14-Cre* mice, referred to as *A17^ΔKC^*. An essentially identical approach yielded *Egfr^flox/flox^ Krt14-Cre* mice, referred to as *Egfr^ΔKC^.* In both cases, the genotypes of the offspring followed a Mendelian distribution. Transgenic *ROSA26-LacZ* reporter mice were from The Jackson Laboratory (003309, B6.129S4-Gt(ROSA)26Sortm1Sor/J). All mice were of mixed genetic background (129Sv, C57BL/6), and all comparisons were between littermates. Serum sodium concentrations were measured on a Chemistry Analyzer (AU400; Beckman Coulter). In some experiments, mice received daily applications of TGF-α (1.5 µg/mouse) or vehicle (80% DMSO in PBS) on their ventral neck and one ear. For depletion of skin macrophages, we subcutaneously injected 100 µl of Clodronate-loaded liposomes or PBS-loaded liposomes as control every other day into the back skin of *A17^ΔKC^* or *Egfr^ΔKC^* mice and their control littermates starting at P8 until P18. Clodronate- or PBS-loaded liposomes were prepared as described previously ([@bib64]). The mice were maintained in the Hospital for Special Surgery (HSS) Animal Facility and at the Biomedical Research Centre of the University Medical Center in Freiburg, and all experiments were performed according to the guidelines of the American Veterinary Association and the German Animal Welfare association and approved by the HSS Internal Animal Care and Use Committee or the Regierungspräsidium Freiburg.

### Tissue histology of the Krt14-Cre/ROSA26Lac-Z reporter mice.

The tissue expression pattern of the keratin 14 promoter was analyzed using offspring of matings of *Adam17^wt/flox^Krt14-Cre* mice with *Adam17^flox/flox^ ROSA26-lac-Z* mice (*R26R*), which express β-galactosidase upon Cre-mediated excision of a loxP-flanked STOP codon. The tissues taken from P14 or P28 animals were fixed with 4% PFA in PBS for 2 h and incubated with 5-bromo-4-chloro-3-indolyl β-[d]{.smallcaps}-galactosidase staining solution at 37°C overnight, and subsequently embedded in paraffin. The tissue sections were counterstained with eosin.

### Quantitative RT-PCR analysis.

Total RNA from mouse skin, epidermal splits, or primary keratinocyte cultures was extracted using RNeasy (QIAGEN). 1 µg of total RNA was reverse transcribed using a First Strand cDNA Synthesis kit (Fermentas). Relative quantification of gene expression was performed by real-time qPCR using iQ SYBR-green Supermix on a Thermal Cycler (CFX96 C1000; Bio-Rad Laboratories) according to the manufacturer's protocols. All primer sequences are shown in [Table S1](http://www.jem.org/cgi/content/full/jem.20112258/DC1){#supp1}. Relative expression was normalized for levels of GAPDH. The generation of the correct amplification products was confirmed using agarose gel electrophoresis.

### Primary keratinocyte preparation and cultivation.

Keratinocytes were isolated from the skin of *A17^ΔKC^* or *Egfr^ΔKC^* mice and their wild-type littermates essentially as described ([@bib19]). In brief, the skin was washed with PBS containing 1% antibiotic-antimycotic (Invitrogen, Germany), and epidermis and dermis were detached by overnight digestion with dispase (STEMCELL Technologies) at 4°C. The epidermis was incubated with 0.25% trypsin (wt/vol) and 2 mM EDTA for 30 min at 37°C under vigorous shaking. After stopping the reaction with PBS containing 10% FCS, the keratinocyte suspension was passed through a 45-µm sieve, and 10^5^ cells/cm^2^ were plated in defined serum-free keratinocyte medium (CellnTec) supplemented 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen). The cells were maintained in defined serum-free keratinocyte medium at 37°C in 5% CO2, and medium was replaced every 48 h. Subconfluent cells derived from passages 1--3 were used for the experiments.

### Keratinocyte cell suspension cultures.

Suspension culture on polyhydroxyethyl-methacrylate (poly-HEMA)--coated plates was performed as previously described ([@bib65]). 6-well plates were coated with poly-HEMA (Sigma-Aldrich), followed by extensive PBS washes. 2 ml of cell suspension was added in each coated well and incubated in a humidified incubator with 5% CO2 in air at 37°C for 24 or 48 h. After centrifugation the cell pellets were either used for the preparation of cell lysates or total RNA extraction or for the in vitro detection of TGM activity. For the detection of TGM activity, we attached 24-h suspension-cultured keratinocytes on gelatin-coated coverslips and preincubated them with 1% BSA in 0.1M Tris-HCl, pH 7.4, for 30 min at room temperature. Afterward, we detected the TGM activity as described in the Enzyme activity assays section.

### Histology.

Tissues were fixed in 3.7% buffered formaldehyde or 4% PFA and embedded in paraffin. 5-µm sections were stained with hematoxylin and eosin (H&E) and toluidine blue.

### Immunohistochemistry.

Paraffin sections or cryosections of 5 µm were stained using mAb against Ki67 (1:50; clone TEC-3; Dako), keratin 14 (1:200; clone LL001; Santa Cruz Biotechnology, Inc.), and polyclonal rabbit antibodies against human TGF-α (1:50; R&D systems), keratin1 (1:1,000; Abcam), loricrin (1:1,000; GeneTex), keratin 6, involucrin (1:500; Covance), and TGM1 and TGM3 (both 1:100; Santa Cruz Biotechnology, Inc.). For visualization, the sections were incubated with either biotinylated secondary anti--mouse IgG or anti--rabbit IgG antibodies (Dako) using the VECTASTAIN ABC kit and Nova RED substrate kit (Vector Laboratories) or with Alexa Fluor 488-- or Alexa Fluor 594--conjugated secondary antibodies (Invitrogen), followed by embedding with mounting medium supplemented with DAPI (Vector Laboratories). Epidermal lipids in skin cryosections were visualized using 2.5 µg/ml Nile red for 2 min at RT. Specimens were viewed with a brightfield and epifluorescence microscope (Axio Imager A1 equipped with AxioCam MRm and MRc cameras; Carl Zeiss) using AxioVision software (version 4.8.2; Carl Zeiss) and processed using ImageJ software (version 1.43u; National Institutes of Health).

### Immunoblotting.

For Western blot analysis, the samples were processed as previously described ([@bib19]). The cells and tissues were lysed in 25 mM Tris-HCl, 1% Nonidet P-40, and 0.1 M NaCl, pH 7.4, supplemented with 2 mM EDTA, 5 mM 1,10-ortho-phenanthroline (Sigma-Aldrich), and protease inhibitor cocktail set III (EMD). Epidermal sheets were detached from the dermis by digestion with dispase (STEMCELL Technologies) at 37°C. Tissues were homogenized in lysis buffer on ice with a T18 basic Ultra Turrax (Ika). Total protein content was determined using the BCA protein assay kit (Invitrogen) and 25 µg total protein per sample was separated by electrophoresis on 7 or 10% SDS-polyacrylamide gels. Immunoblots were probed with anti-keratin 14 mAb (Santa Cruz Biotechnology, Inc.), anti-EGFR rabbit pAbs (Cell Signaling Technology) or anti--phospho-EGFR (pY1068, clone EP774Y; Epitomics Inc.), polyclonal rabbit antibodies against the cytoplasmic domain of ADAM17 ([@bib53]), TGM1, TGM3, and Erk1/2 (Santa Cruz Biotechnology, Inc.), phospho-p44/42 MAPK (Thr202/Tyr204; Cell Signaling Technology Inc.), keratin1 (Abcam), loricrin (GeneTex, USA) and involucrin (Covance), and secondary HRP-coupled anti--mouse and anti--rabbit IgG antibodies. Immunoblot signals were quantified with Fusion SL and BIO-1D Advanced software (PeqLab Biotechnologie GmbH).

### Enzyme activity assays.

For in situ detection of TGM activity in skin sections, we used the biotinylated amine donor substrate monodansylcadaverine (biotMDC) as described earlier ([@bib51]). Cryostat sections were air dried and preincubated with 1% BSA in 0.1 M Tris-HCl, pH 7.4 or pH 8.4, for 30 min at room temperature. The sections were then incubated for 2 h with 100 µM biotMDC, 5 mM CaCl~2~, 0.1 M Tris-HCl, pH 7.4 (for TGM1) or pH 8.4 (for TGM1 and TGM3). After stopping the reaction with 10 mM EDTA and extensive PBS washing, the sections were stained with Streptavidin-conjugated Alexa Fluor 488 (Invitrogen) and DAPI-supplemented mounting medium. For in situ detection of serine protease activity in cryostat sections of skin, we incubated 0.5 µg/ml of the SBTI Alexa Fluor 488 conjugate in 1% BSA in 0.1 M Tris-HCl, pH 7.4, for 20 min at room temperature. Negative controls were incubated with excess concentrations of uncoupled SBTI. After extensive washing, the sections were processed with DAPI supplemented mounting medium.

### ELISA.

TGF-α released from confluent keratinocytes in a 3.5-cm cell culture plate for 24 h was measured with an ELISA kit for human TGF-α (RayBiotech, Inc.) according to the manufacturer's protocols. The supernatants were concentrated by 70% ethanol precipitation. Ig isotype sandwich ELISAs were performed by standard procedures. 96-well microtiter plates (NUNC) were coated with rat anti--mouse IgG1 (Invitrogen), IgG2a, IgM (BD), and sheep anti--mouse IgE (The Binding Site Group, Ltd.) and detection by HRP-coupled anti--mouse IgG1, IgG2a, IgM, and biotinylated anti--mouse IgE (all BD). Standard immunoglobulins were purchased from Sigma-Aldrich.

### Preparation of CEs.

A defined area of dorsal mouse skin (25 mm^2^) was boiled in isolation buffer (20 mM Tris-HCl, pH 7.5, 5 mM EDTA, 10 mM DTT, and 2% SDS) under vigorous shaking for 40 min. After centrifugation, the CEs were washed twice with isolation buffer and were analyzed using a hemocytometer ([@bib2]).

### Detection of TEWL and dye exclusion assay.

The TEWL on shaved back skin was measured with a Tewameter (TM-300; Courage and Khazaka). For toluidine blue staining, newborn to P15 mice were sacrificed and dehydrated by sequential incubation in 25, 50, 75, and 100% methanol. After rehydration in PBS, they were incubated for 10 min in 0.01% toluidine blue and destained with PBS.

### Flow cytometry.

Bone marrow cells were flushed from femurs and tibias with PBS using a 27G needle and passed through a 70-µm sieve. Skin cell suspensions were obtained from defined areas of ventral neck skin and one ear (400 mm^2^). Skin was minced and incubated in Hank's Balanced Salt Solution buffer containing 2.4 U liberase DH and 100 µg/ml DNase I (Roche) for 2 h under vigorous shaking and the cell suspension was passed through a 45-µm sieve, and the cells were stained with the following antibody conjugates: biotinylated anti-CD45, anti-CD115 PE, anti-CD11b PE-Cy7 (eBioscience), anti-CD3 FITC, anti-B220 PE, anti-CD19 PE, anti-CD117 PECy7, anti-FcεRIα PE, anti-Ly6G FITC, anti-Ly6C PerCP-Cy5.5 (BD), and anti-F4/80 APC (Serotec). Biotin-conjugated Abs were revealed with Streptavidin eFluor 450 (eBioscience). Data were acquired and analyzed on a Beckman Coulter Gallios instrument using Kaluza software (Beckman Coulter).

### Microarray processing and data analysis.

Total RNA from P10 full back skin of either two *A17^ΔKC^* or two wild-type littermate mice was prepared using the RNeasy Fibrous Tissue Mini kit (QIAGEN). After determination of the RNA concentration (NanoDrop ND-1000; Wilmington) and of RNA quality with a 2100 Bioanalyzer (Agilent Technologies), the samples were further processed for transcriptome analyses with the Agilent 4 × 44K whole mouse genome oligo expression microarray kit (Design ID 014868) according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol. The raw data were analyzed using GeneSpring GX 10.0 (normalization: shift to 75^th^ percentile, baseline transformation: median of all samples). The normalized data were filtered to exclude probes flagged absent in all samples. The remaining probes were tested for statistical significance of expression using a two-sample Student's *t* test (unpaired) with asymptotic p-value computation and a cut off of 0.05. Multiple testing correction was performed according to Benjamini-Hochberg ([@bib29]; P ≤ 0.05). The cutoff for the fold change is ≤2 (1 log2) up- or down-regulation.

### Statistics.

All parametric data are present as mean ± SD. Data of two groups were analyzed for significance using the Student's *t* test and the statistical analysis of survival curves was performed using the Mantel-Cox test. Both calculations were performed with Prism version 5.0 (GraphPad Software). For all analyses, *n* = number of experiments, and differences are considered to be statistically significant at P \< 0.05.

### Online supplemental material.

Table S1 lists the primer sequences used for quantitative RT-PCR analysis. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20112258/DC1>.
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